Richard Wurtman

Richard Wurtman
Born March 9, 1936 (1936-03-09) (age 80)
Philadelphia, Pennsylvania, United States
Fields Neuroscience, Treatments for Brain Diseases, Nutrition and the Brain
Institutions MIT, Harvard
Alma mater
Known for
  • Invention of use of melatonin to promote sleep
  • Use of serotoninergic drugs to treat obesity and other disorders characterized by disturbances in both appetite and mood
  • Strategies for finding drugs to treat Alzheimer's Disease; (Wurtman, 2009)
  • Use of their circulating precursors to increase the syntheses of brain neurotransmitters and membranes

Richard Wurtman, M.D., is the Cecil H. Green Distinguished Professor at the Massachusetts Institute of Technology and a Professor of Neuroscience in MIT’s Department of Brain & Cognitive Sciences, and of Neuropharmacology in the Harvard – MIT Division of Health Sciences & Technology.

His research career encompasses three areas:

One of the earliest areas of Wurtman's focus was in dietary precurors of neurotransmitters such as acetylcholine.[1]
Along with Nicholas Zervas of Beth Israel Hospital and Harvard Medical School, another early area of Wurtman's research pertained to the neurotransmitter dopamine, and its role in stroke physiology.[2] Wurtman's studies occurred at a time of significant growth in research and understanding of neurotransmitters, with optimistic expectations for practical outcomes.[3]

Research performed in Wurtman's laboratory has generated about 1,000 research articles and 200 patents.[4]

Among discoveries from Wurtman's laboratory have been that

With wife Judith Wurtman, Wurtman co-edited an eight-volume series of books on “Nutrition and the Brain”, and with John Growdon, M.D. and Suzanne Corkin, Ph.D., a nine volume series on Alzheimer’s disease.

Wurtman co-founded Interneuron Pharmaceuticals in 1988,[10][11] which was renamed to Indevus in 2002.[12] Indevus brought an in-licensed product, Trospium chloride, to market before being acquired by Endo Pharmaceuticals in 2009 for $370.0M in cash and $267.0M in milestones.[11]

He also founded Back Bay Scientific, Inc..

He established the Center for Brain Sciences and Metabolism Charitable Trust, and serves as its Scientific Director.

Publications

Among Wurtman's publications are the following (see external links below for the link to a pdf file of a more complete list):

References

  1. Cohen, Edith L; Wurtman, Richard J (Feb 13, 1976), "Brain Acetylcholine: Control by Dietary Choline" (PDF), Science, 191 (4227): 561–562, doi:10.1126/science.1251187, PMID 1251187, retrieved 3 October 2010
  2. "Medicine: Hope for Stroke Victims", Time, Apr 29, 1974, retrieved 3 October 2010
  3. "Behavior: Better Living Through Biochemistry", Time, Apr 2, 1979, retrieved 3 October 2010  See p.3 for mention of Wurtman's studies
  4. Wurtman Lab
  5. Beardsley, Tim (April 1, 1996), "Melatonin Mania: Separating the facts from the hype", Scientific American, retrieved 4 October 2010
  6. Matthew Herper for Forbes. Sept 25, 2002 A Biotech Phoenix Could Be Rising
  7. FDA September 15, 1997. FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)
  8. Lemonick, Michael D; Nash, J. Madeleine; Park, Alice; Thompson, Dick (Sep 29, 1997). "Redux patent and controversy". In . The Mood Molecule. Time. Retrieved 4 October 2010.
  9. New approach to fighting Alzheimer’s, MIT News Office
  10. Lemonick, Michael D; Dowell, William; Nash, J. Madeleine; Ramirez, Ainissa; Reid, Brian; Ressner, Jeffrey (Sep 23, 1996). "Wurtman as co-founder of Interneuron Pharmaceuticals". In . The New Miracle Drug?. Time. Retrieved 3 October 2010.
  11. 1 2 BioCentury listing for Indevus Page accessed May 13, 2016
  12. Indevus Press Release April 2, 2002
This article is issued from Wikipedia - version of the 10/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.